In this randomized clinical trial of 149 adults with type 2 diabetes, the glycemic control of the artificial intelligence–based insulin clinical decision support system intervention was not inferior to that of standard therapy by senior physicians, without increasing risk of adverse events. The gene discussed is INS; the disease is type 2 diabetes mellitus.